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Age at Prior Response CurrentPt # diagnosis Marrow Treatment to CLO Status1 11 11q23 1-Ara-C/
Dauno/
6-TG (induction
failure)CR (2) Died with
fungal sepsis2 8 11q23 1-Ara-C/
Dauno/VP/
L-ASP (CR-1)CR (1) CR continues
after 7 cycles
of CLO but
has chronic
thrombocytopenia3 13 t(8;21) 1-Ara-C/
Dauno/etoposide/
IT1Ara-C/
Mito (CR-1)CR (1) In CR,
undergoing BMT4 4 Monosomy 7 1-Ara-C/VP/
Dauno/
etoposide
(CR-1)CR (1) Relapsed after
2nd BMT,
undergoing
induction
with CLO5 10 Monosomy
5, 181-Ara-C/
etoposide/
6-TG/Dauno/
gemtuzumab/
Mito/IT 1
Ara-C (PR)No response
(1)Died of
progressive disease
and toxicities
following
BMT6 1.5 Noninformative 1-Ara-C/
Dauno/
etoposide/
6-TG/Mito/No response
(1)Died of
progressive
diseaseCLO: clofarabine; Ara-C: cytarabine; Dauno: daunorubicin; 6-TG: 6-thi-
oguanine; CR: complete remission; VP: etoposide1 cisplatin; L-ASP: L-
asparaginase; IT: ifosfamide1 paclitaxel; Mito: mitoxantrone; PR: partial
response.LYMPHOMA/MULTIPLE MYELOMA
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Autologous transplantation results in improved outcomes in pa-
tients with multiple myeloma (MM), but patients relapse from
persistent disease. A promising area of investigation is the develop-
ment of cancer vaccines that educate host immunity to target mye-
loma cells. We have developed a cancer vaccine in which DCs are
fused to autologous MM cells. We are conducting a study in which
patients with MM undergo stem cell transplantation followed by
post-transplant vaccination with DC/MM fusions. DCs were gener-
ated from adherent mononuclear cells cultured with GM-CSF and
IL-4 and TNFa. Myeloma cells were isolated from bone marrow as-
pirates. DC and MM cells were fused with polyethylene glycol. To
date, 26 patients have been enrolled. Mean yield of the DC and my-
eloma preparations was 171  106 and 70  106 cells, respectively.
Mean fusion efficiency was 40% and the mean cell dose generated
was 4 106 fusion cells. As ameasure of their potency as antigen pre-
senting cells, fusion cells potently stimulated allogeneic T cell pro-
liferation in vitro. Mean stimulation indexes were 12, 57, 31 for T
cells stimulated by MM cells, DCs, and fusions. Adverse events
were mild. 14 patients have completed vaccinations of which 8have achieved a complete remission and 6 a partial remission. Of
note, 4 patients achieved complete remission only with vaccination.
T cell responses to PHA and tetanus toxoid were depressed post-
transplant. In contrast, a significant increase was noted post-trans-
plant in circulating tumor reactive lymphocytes as determined by
T cell expression of IFNg following ex vivo exposure to autologous
myeloma cell lysate (Mean percentage of tumor reactive CD8 cells
was 0.9 and 11 pre and post-transplant, respectively p 5 0.01;
mean percentage of CD4 cells was 0.7 and 2.7; p 5 0.02). A further
amplification of tumor reactive lymphocytes was seen with vaccina-
tion (mean percentage of CD4 and CD8 tumor reactive T cells was
4.9 and 15, respectively). A decrease in circulating regulatory T cells
was observed following transplantation. In summary, fusion cell
vaccination in conjunction with stem cell transplantation was well
tolerated, induced anti-tumor immunity and clinical responses.
The post-transplant period is characterized by decreased levels of
regulatory T cells and enhanced levels of tumor reactive T cells.
The increase in tumor reactive T cells post-transplant is further
amplified following vaccination with DC/MM fusion cells.175
PRODUCTION OF MAGE-A4-SPECIFIC CTL FROM HEALTHY DONORS,
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Patientswho relapsewithHodgkin’s Lymphoma (HL) – often pre-
senting with chemo- and radio- resistant disease – may benefit from
immunotherapeutic strategies as adjuvant or salvage therapy after he-
matopoietic stem cell transplantation (HSCT). We have previously
demonstrated that infusion of cytotoxic T cells directed against Ep-
stein Barr virus (EBV)-derived proteins expressed in tumors induced
complete remissions in patients with relapsed EBV-positive HL.
However, approximately 70% of relapsed lymphomas are EBV-
negative. Therefore, we investigated the use of another immunother-
apeutic target, the cancer/testis antigen MAGE-A4, which is
frequently expressed by Hodgkin Reed Sternberg cells. The re-
stricted expression of this protein in immune-privileged germ cells
andmalignant cells makes it an attractive target for the ex vivo gener-
ation of tumor-specific T cells. Using dendritic cells pulsed with an
overlapping peptide library spanning the entire MAGE A4 protein
as antigen presenting cells, and culturing responder T cells in the
presence of the cytokines IL7, IL12, and IL15, we have successfully
expandedMAGE-A4-specificT cells fromdifferent sources of hema-
topoietic stem cells: patients with Hodgkin’s Lymphoma (n 5 3),
healthy donors (n 5 5), and umbilical cord blood (n 5 1). After 2
weeks expansion, 4of 8CTL lines contained ameanof 62.62%(range
49.55 – 79.86%) CD81 and 11.41% (range 1.64 – 17.88%) CD41
T-cells. ELISPOT assays on CTL lines demonstrated a mean of
147.54 (range 29–716) IFNg-producing cells (IPC)/1 10e5T-cells
following incubation with MAGE A4 peptides. No significant re-
sponse to irrelevant peptides was demonstrated (mean 9.14; range
2–21.5 IPC/10e5 cells). Peptide pool mapping allowed us to identify
a single, previously uncharacterized epitope (aa266–285, the NPAR-
YEFLWGPRALAETSYV peptide) in the majority of healthy do-
nors. Additional analysis on an evaluable CTL line showed that the
response to the NPA peptide was mediated by CD81T cells, which
demonstrated cytotoxic activity against peptide-pulsed autologous
targets using the Cr51 release assay. These early results suggest that
adoptive immunotherapy utilizing allogeneic, autologous or umbili-
cal cord blood as sources of T cells is a promising approach for the
treatment of relapsed HL after stem cell transplant.176
BORTEZOMIB TARGETS STROMA-MEDIATED APO2L/TRAIL APOPTOSIS
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APO2L/TRAIL mediates graft versus tumor (GVT) responses
while sparing normal tissues. We have shown that stroma promotes
